Literature DB >> 21315721

Survivors of childhood cancer have increased risk of gastrointestinal complications later in life.

Robert Goldsby1, Yan Chen, Shannon Raber, Linda Li, Karen Diefenbach, Margarett Shnorhavorian, Nina Kadan-Lottick, Fay Kastrinos, Yutaka Yasui, Marilyn Stovall, Kevin Oeffinger, Charles Sklar, Gregory T Armstrong, Leslie L Robison, Lisa Diller.   

Abstract

BACKGROUND & AIMS: Children who receive cancer therapy experience numerous acute gastrointestinal (GI) toxicities. However, the long-term GI consequences have not been extensively studied. We evaluated the incidence of long-term GI outcomes and identified treatment-related risk factors.
METHODS: Upper GI, hepatic, and lower GI adverse outcomes were assessed in cases from participants in the Childhood Cancer Survivor Study, a study of 14,358 survivors of childhood cancer who were diagnosed between 1970 and 1986; data were compared with those from randomly selected siblings. The median age at cancer diagnosis was 6.8 years (range, 0-21.0 years), and the median age at outcome assessment was 23.2 years (5.6-48.9 years) for survivors and 26.6 years (1.8-56.2 years) for siblings. Rates of self-reported late GI complications (occurred 5 or more years after cancer diagnosis) were determined and associated with patient characteristics and cancer treatments, adjusting for age, sex, and race.
RESULTS: Compared with siblings, survivors had increased risk of late-onset complications of the upper GI tract (rate ratio [RR], 1.8; 95% confidence interval [CI], 1.6-2.0), liver (RR, 2.1; 95% CI, 1.8-2.5), and lower GI tract (RR, 1.9; 95% CI, 1.7-2.2). The RRs for requiring colostomy/ileostomy, liver biopsy, or developing cirrhosis were 5.6 (95% CI, 2.4-13.1), 24.1 (95% CI, 7.5-77.8), and 8.9 (95% CI, 2.0-40.0), respectively. Older age at diagnosis, intensified therapy, abdominal radiation, and abdominal surgery increased the risk of certain GI complications.
CONCLUSIONS: Individuals who received therapy for cancer during childhood have an increased risk of developing GI complications later in life.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21315721      PMCID: PMC3081911          DOI: 10.1053/j.gastro.2011.01.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  26 in total

1.  Acute and late effects of multimodal therapy on normal tissues.

Authors:  T L Phillips; K K Fu
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

2.  Estimating the distribution of times from HIV seroconversion to AIDS using multiple imputation. Multicentre AIDS Cohort Study.

Authors:  J M Taylor; A Muñoz; S M Bass; A J Saah; J S Chmiel; L A Kingsley
Journal:  Stat Med       Date:  1990-05       Impact factor: 2.373

3.  Hepatitis C infection among survivors of childhood cancer.

Authors:  D K Strickland; C A Riely; C C Patrick; D Jones-Wallace; J M Boyett; B Waters; J F Fleckenstein; P J Dean; R Davila; T E Caver; M M Hudson
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

4.  Longitudinal data analysis for discrete and continuous outcomes.

Authors:  S L Zeger; K Y Liang
Journal:  Biometrics       Date:  1986-03       Impact factor: 2.571

5.  Anthracycline toxicity.

Authors:  K Y Wong; B C Lampkin
Journal:  Am J Pediatr Hematol Oncol       Date:  1983

6.  Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study.

Authors:  Meagan Lansdale; Sharon Castellino; Neyssa Marina; Pamela Goodman; Melissa M Hudson; Ann C Mertens; Stephanie M Smith; Wendy Leisenring; Leslie L Robison; Kevin C Oeffinger
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

Review 7.  Bowel injury: current and evolving management strategies.

Authors:  Martin Hauer-Jensen; Junru Wang; James W Denham
Journal:  Semin Radiat Oncol       Date:  2003-07       Impact factor: 5.934

8.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.

Authors:  S E Lipshultz; S D Colan; R D Gelber; A R Perez-Atayde; S E Sallan; S P Sanders
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

9.  Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project.

Authors:  Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer
Journal:  Med Pediatr Oncol       Date:  2002-04

10.  Characteristics of childhood cancer survivors predicted their successful tracing.

Authors:  Ann C Mertens; Roberta Sposato Walls; Leslie Taylor; Pauline A Mitby; John Whitton; Peter D Inskip; John D Potter; Leslie L Robison
Journal:  J Clin Epidemiol       Date:  2004-09       Impact factor: 7.407

View more
  15 in total

1.  Incidence of and risk factors for late cholecystectomy in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Authors:  Bryan V Dieffenbach; Nan Li; Arin L Madenci; Andrew J Murphy; Dana Barnea; Todd M Gibson; Emily S Tonorezos; Wendy M Leisenring; Rebecca M Howell; Lisa R Diller; Qi Liu; Eric J Chow; Gregory T Armstrong; Yutaka Yasui; Kevin C Oeffinger; Christopher B Weldon; Brent R Weil
Journal:  Eur J Cancer       Date:  2020-05-15       Impact factor: 9.162

2.  Late-onset anorectal disease and psychosocial impact in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.

Authors:  Arin L Madenci; Bryan V Dieffenbach; Qi Liu; Daisuke Yoneoka; Jamie Knell; Todd M Gibson; Yutaka Yasui; Wendy M Leisenring; Rebecca M Howell; Lisa R Diller; Kevin R Krull; Gregory T Armstrong; Kevin C Oeffinger; Andrew J Murphy; Brent R Weil; Christopher B Weldon
Journal:  Cancer       Date:  2019-07-19       Impact factor: 6.860

3.  A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment.

Authors:  Anne E Kazak; Matthew C Hocking; Richard F Ittenbach; Anna T Meadows; Wendy Hobbie; Branlyn Werba DeRosa; Ann Leahey; Leslie Kersun; Anne Reilly
Journal:  Pediatr Blood Cancer       Date:  2011-08-19       Impact factor: 3.167

4.  Hepatic late adverse effects after antineoplastic treatment for childhood cancer.

Authors:  Renée L Mulder; Dorine Bresters; Malon Van den Hof; Bart Gp Koot; Sharon M Castellino; Yoon Kong K Loke; Piet N Post; Aleida Postma; László P Szőnyi; Gill A Levitt; Edit Bardi; Roderick Skinner; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2019-04-15

5.  Adaptations to a Generalized Radiation Dose Reconstruction Methodology for Use in Epidemiologic Studies: An Update from the MD Anderson Late Effect Group.

Authors:  Rebecca M Howell; Susan A Smith; Rita E Weathers; Stephen F Kry; Marilyn Stovall
Journal:  Radiat Res       Date:  2019-06-18       Impact factor: 2.841

Review 6.  [Delayed effects of oncological therapy].

Authors:  H Biersack; G Brabant
Journal:  Internist (Berl)       Date:  2013-10       Impact factor: 0.743

7.  Intestinal Obstruction in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.

Authors:  Arin L Madenci; Stacey Fisher; Lisa R Diller; Robert E Goldsby; Wendy M Leisenring; Kevin C Oeffinger; Leslie L Robison; Charles A Sklar; Marilyn Stovall; Rita E Weathers; Gregory T Armstrong; Yutaka Yasui; Christopher B Weldon
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

Review 8.  Survivors of childhood and adolescent cancer: life-long risks and responsibilities.

Authors:  Leslie L Robison; Melissa M Hudson
Journal:  Nat Rev Cancer       Date:  2013-12-05       Impact factor: 60.716

9.  Esophageal disease among childhood cancer survivors-A report from the Childhood Cancer Survivors Study.

Authors:  Peter H Asdahl; Kevin C Oeffinger; Vanna Albieri; Melissa Hudson; Wendy M Leisenring; Sarah S Donaldson; Henrik Hasle; Jeanette F Winther; Gregory T Armstrong; Leslie L Robison
Journal:  Pediatr Blood Cancer       Date:  2021-04-12       Impact factor: 3.838

10.  Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study.

Authors:  Mari Wilhelmsson; Heidi Glosli; Marianne Ifversen; Jonas Abrahamsson; Jacek Winiarski; Kirsi Jahnukainen; Henrik Hasle
Journal:  Bone Marrow Transplant       Date:  2018-09-21       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.